Skye Bioscience (NASDAQ:SKYE – Get Free Report) and VYNE Therapeutics (NASDAQ:VYNE – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings and institutional ownership.
Institutional & Insider Ownership
21.1% of Skye Bioscience shares are held by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are held by institutional investors. 3.0% of Skye Bioscience shares are held by insiders. Comparatively, 4.8% of VYNE Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Skye Bioscience and VYNE Therapeutics’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Skye Bioscience | N/A | -45.78% | -37.44% |
VYNE Therapeutics | -6,896.55% | -43.73% | -38.55% |
Risk and Volatility
Analyst Ratings
This is a summary of recent recommendations and price targets for Skye Bioscience and VYNE Therapeutics, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Skye Bioscience | 0 | 0 | 6 | 0 | 3.00 |
VYNE Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
Skye Bioscience currently has a consensus target price of $18.67, suggesting a potential upside of 502.15%. VYNE Therapeutics has a consensus target price of $6.88, suggesting a potential upside of 75.38%. Given Skye Bioscience’s higher probable upside, equities research analysts plainly believe Skye Bioscience is more favorable than VYNE Therapeutics.
Earnings & Valuation
This table compares Skye Bioscience and VYNE Therapeutics”s revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Skye Bioscience | N/A | N/A | -$37.65 million | N/A | N/A |
VYNE Therapeutics | $493,000.00 | 117.29 | -$28.45 million | ($0.86) | -4.56 |
VYNE Therapeutics has higher revenue and earnings than Skye Bioscience.
About Skye Bioscience
Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.
About VYNE Therapeutics
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Receive News & Ratings for Skye Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Skye Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.